Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹200 | ₹500 |
Expense Ratio | 2.45 | 1.93 |
NAV | ₹29.88 | ₹436.94 |
Fund Started | 08 Feb 2019 | 04 Jun 1999 |
Fund Size | ₹85.19 Cr | ₹3933.26 Cr |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 1.19% | 6.67% |
3 Year | 19.61% | 25.10% |
5 Year | 14.08% | 19.64% |
1 Year
3 Year
5 Year
Equity | 97.83% | 96.36% |
Cash | 2.17% | 3.56% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.08% |
Apollo Hospitals Enterprise Ltd. | 5.85% |
Torrent Pharmaceuticals Ltd. | 5.55% |
Cipla Ltd. | 5.51% |
Fortis Healthcare Ltd. | 4.79% |
Piramal Pharma Ltd. | 4.45% |
Neuland Laboratories Ltd. | 4.14% |
Divi's Laboratories Ltd. | 4.11% |
Aurobindo Pharma Ltd. | 3.98% |
Alkem Laboratories Ltd. | 3.96% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.94% |
Divi's Laboratories Ltd. | 6.36% |
Max Healthcare Institute Ltd. | 5.67% |
Cipla Ltd. | 4.59% |
Lupin Ltd. | 4.08% |
Lonza Group Ag | 4.06% |
Fortis Healthcare Ltd. | 3.70% |
Torrent Pharmaceuticals Ltd. | 3.66% |
Gland Pharma Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.34% |
Name | Karan Doshi | Tanmaya Desai |
Start Date | 31 Jul 2023 | 17 May 2024 |
Name
Start Date
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 08 Feb 2019 | 04 Jun 1999 |
Description
Launch Date